Cell type specific gene delivery by lentiviral vectors: New options in immunotherapy

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Zhou, Qi ^a   Buchholz, Christian J ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

CD8+ T lymphocytes; Gene transfer; Lentiviral vector; Targeting; Tumor

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OKT 8; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; CD8 ANTIGEN GENE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELL SURFACE; CELL TYPE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG EFFICACY; GENE; GENETIC TRANSFECTION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA; MOLECULAR DYNAMICS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE; TARGET CELL DESTRUCTION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

EID: 84884846771     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22566     Document Type: Article

References (10)

1. Sheridan C. Gene therapy finds its niche. Nat Biotechnol 2011; 29:121-8; PMID:21301435; http:// dx.doi.org/10.1038/nbt.1769.
2. Russo V, Bondanza A, Ciceri F, Bregni M, Bordignon C, Traversari C, et al. A dual role for genetically modified lymphocytes in cancer immunotherapy. Trends Mol Med 2012; 18:193-200; PMID:22230382; http:// dx.doi.org/10.1016/j.molmed.2011.12.003.
3. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191.
4. Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, Brynza J, et al. Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 2010; 7:929-35; PMID:20935652; http://dx.doi.org/10.1038/ nmeth.1514
5. Buchholz CJ, Mühlebach MD, Cichutek K. Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer Trends Biotechnol 2009; 27:259-65; PMID:19327858; http://dx.doi.org/10.1016/j. tibtech.2009.02.002.
6. Münch RC, Mühlebach MD, Schaser T, Kneissl S, Jost C, Plückthun A, et al. DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther 2011; 19:686-93; PMID:21224833; http://dx.doi.org/10.1038/ mt.2010.298.
7. Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, Cattaneo R, et al. Targeted cell entry of lentiviral vectors. Mol Ther 2008; 16:1427-36; PMID:18578012; http://dx.doi.org/10.1038/mt.2008.128.
8. Ageichik A, Buchholz CJ, Collins MK. Lentiviral vectors targeted to MHC II are effective in immunization. Hum Gene Ther 2011; 22:1249-54; PMID:21247346; http://dx.doi.org/10.1089/hum.2010.184.
9. Zhou Q, Schneider IC, Edes I, Honegger A, Bach P, Schönfeld K, et al. T cell receptor gene transfer exclusively to human CD8+ cells enhances tumor cell killing. Blood 2012; In press; PMID:22898597; http:// dx.doi.org/10.1182/blood-2012-02-412973.
10. Clement M, Ladell K, Ekeruche-Makinde J, Miles JJ, Edwards ES, Dolton G, et al. Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. J Immunol 2011; 187:654-63; PMID:21677135; http://dx.doi.org/10.4049/jimmunol. 1003941